or Try an Advanced Search...

    Technical Analysis for REPL - Replimune Group, Inc.

    Grade Last Price % Change Price Change
    C 9.36 4.00% 0.36
    REPL closed up 4.0 percent on Monday, July 1, 2024, on 88 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical REPL trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Outside Day Range Expansion 4.00%
    Wide Bands Range Expansion 4.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 9.86%
    Wide Bands Range Expansion 9.86%
    NR7 Range Contraction 7.46%
    Wide Bands Range Expansion 7.46%
    Spinning Top Other 6.12%
    Inside Day Range Contraction 6.12%
    Older End-of-Day Signals for REPL ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Resistance about 5 hours ago
    Up 5% about 5 hours ago
    Up 3% about 5 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 2% about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    REPL Chart by TradingView
    Basic chart:

    Profile

    Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

    Is REPL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 13 Replimune to raise ~$100M in private financing
    Jun 13 Replimune Announces $100 Million Private Placement Financing
    Jun 7 Replimune (REPL) Gains on Positive Data From Melanoma Study
    Jun 7 Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    Jun 6 Sector Update: Health Care Stocks Higher in Late Afternoon Trading
    Jun 6 Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
    Jun 6 Replimune up 30% on results for RP1 combo in melanoma
    Jun 6 Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
    Jun 3 Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 23 Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    See more REPL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.61
    52 Week Low 4.92
    Average Volume 1,315,594
    200-Day Moving Average 9.42
    50-Day Moving Average 6.95
    20-Day Moving Average 8.04
    10-Day Moving Average 8.50
    Average True Range 0.70
    RSI (14) 65.75
    ADX 28.86
    +DI 32.77
    -DI 16.50
    Chandelier Exit (Long, 3 ATRs) 7.66
    Chandelier Exit (Short, 3 ATRs) 7.03
    Upper Bollinger Bands 10.57
    Lower Bollinger Band 5.50
    Percent B (%b) 0.76
    BandWidth 63.08
    MACD Line 0.64
    MACD Signal Line 0.56
    MACD Histogram 0.0791
    Fundamentals Value
    Market Cap 574.59 Million
    Num Shares 61.4 Million
    EPS -3.16
    Price-to-Earnings (P/E) Ratio -2.96
    Price-to-Sales 0.00
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.35
    Resistance 3 (R3) 10.28 9.89 10.19
    Resistance 2 (R2) 9.89 9.63 9.92 10.13
    Resistance 1 (R1) 9.62 9.48 9.76 9.69 10.07
    Pivot Point 9.23 9.23 9.29 9.26 9.23
    Support 1 (S1) 8.96 8.97 9.10 9.03 8.65
    Support 2 (S2) 8.57 8.82 8.60 8.59
    Support 3 (S3) 8.30 8.57 8.54
    Support 4 (S4) 8.37